Compare NBB & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBB | FLGT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.9M | 525.3M |
| IPO Year | 2010 | 2016 |
| Metric | NBB | FLGT |
|---|---|---|
| Price | $15.66 | $18.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 50.8K | ★ 487.6K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | N/A | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.95 | $13.46 |
| 52 Week High | $16.62 | $31.04 |
| Indicator | NBB | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 64.47 |
| Support Level | $15.51 | $13.91 |
| Resistance Level | $16.04 | $22.66 |
| Average True Range (ATR) | 0.23 | 0.86 |
| MACD | 0.00 | 0.22 |
| Stochastic Oscillator | 48.33 | 75.69 |
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.